These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38009241)

  • 1. A phase 2 open-label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema.
    Petersen RS; Bordone L; Riedl MA; Tachdjian R; Craig TJ; Lumry WR; Manning ME; Bernstein JA; Raasch J; Zuraw BL; Deng Y; Newman KB; Alexander VJ; Lui C; Schneider E; Cohn DM
    Allergy; 2024 Mar; 79(3):724-734. PubMed ID: 38009241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Prekallikrein for Hereditary Angioedema.
    Fijen LM; Riedl MA; Bordone L; Bernstein JA; Raasch J; Tachdjian R; Craig T; Lumry WR; Manning ME; Alexander VJ; Newman KB; Revenko A; Baker BF; Nanavati C; MacLeod AR; Schneider E; Cohn DM
    N Engl J Med; 2022 Mar; 386(11):1026-1033. PubMed ID: 35294812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
    Riedl MA; Tachdjian R; Lumry WR; Craig T; Karakaya G; Gelincik A; Stobiecki M; Jacobs JS; Gokmen NM; Reshef A; Gompels MM; Manning ME; Bordone L; Newman KB; Treadwell S; Wang S; Yarlas A; Cohn DM;
    N Engl J Med; 2024 Jul; 391(1):21-31. PubMed ID: 38819395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Daily Oral Berotralstat for Long-Term Prophylaxis of Hereditary Angioedema: The Open-Label Extension of the APeX-2 Randomized Trial.
    Kiani-Alikhan S; Gower R; Craig T; Wedner HJ; Kinaciyan T; Aygören-Pürsün E; Banerji A; Bernstein JA; Anderson J; Collis P; Johnston DT; Desai B; Tomita D; Gagnon R; Tachdjian R; Soteres DF; Farkas H; Caballero T; McNeil D; Jacobs J; Lumry WR;
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):733-743.e10. PubMed ID: 38122865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema.
    Riedl MA; Bordone L; Revenko A; Newman KB; Cohn DM
    J Allergy Clin Immunol Pract; 2024 Apr; 12(4):911-918. PubMed ID: 38142864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
    Hide M; Ohsawa I; Nurse C; Yu M;
    J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, pharmacokinetics, and safety of subcutaneous C1-esterase inhibitor as prophylaxis in Japanese patients with hereditary angioedema: Results of a Phase 3 study.
    Fukuda T; Yamagami K; Kawahata K; Suzuki Y; Sasaki Y; Miyagi T; Jacobs I; Lawo JP; Glassman F; Akama H; Hide M; Ohsawa I
    Allergol Int; 2023 Jul; 72(3):451-457. PubMed ID: 36858856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies.
    Farkas H; Balla Z
    Expert Opin Investig Drugs; 2024 Mar; 33(3):191-200. PubMed ID: 38366937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive Treatment of Hereditary Angioedema: A Review of Phase III Clinical Trial Data for Subcutaneous C1 Inhibitor and Relevance for Patient Management.
    West JB; Poarch K; Lumry WR
    Clin Ther; 2021 Dec; 43(12):2154-2166.e1. PubMed ID: 34879971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema.
    Levy D; Caballero T; Hussain I; Reshef A; Anderson J; Baker J; Schwartz LB; Cicardi M; Prusty S; Feuersenger H; Pragst I; Manning ME
    Pediatr Allergy Immunol Pulmonol; 2020 Sep; 33(3):136-141. PubMed ID: 32953229
    [No Abstract]   [Full Text] [Related]  

  • 13. [EFFICACY, PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF INTRAVENOUS C1 INHIBITOR FOR LONG-TERM PROPHYLAXIS AND TREATMENT OF BREAKTHROUGH ATTACKS IN JAPANESE SUBJECTS WITH HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Fukunaga A; Morita E; Miyagi T; Eto K; Shimizu A; Kagami S; Yamamoto H; Vardi M; Tang Y; Wang Y; Hide M
    Arerugi; 2020; 69(3):192-203. PubMed ID: 32435020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
    Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
    Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.
    Aygören-Pürsün E; Soteres D; Moldovan D; Christensen J; Van Leerberghe A; Hao J; Schranz J; Jacobson KW; Martinez-Saguer I
    Int Arch Allergy Immunol; 2017; 173(2):114-119. PubMed ID: 28662509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
    Valerieva A; Longhurst HJ
    Front Allergy; 2022; 3():952233. PubMed ID: 36172291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial.
    Ohsawa I; Honda D; Suzuki Y; Fukuda T; Kohga K; Morita E; Moriwaki S; Ishikawa O; Sasaki Y; Tago M; Chittick G; Cornpropst M; Murray SC; Dobo SM; Nagy E; Van Dyke S; Reese L; Best JM; Iocca H; Collis P; Sheridan WP; Hide M
    Allergy; 2021 Jun; 76(6):1789-1799. PubMed ID: 33247955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
    Reshef A; Hsu C; Katelaris CH; Li PH; Magerl M; Yamagami K; Guilarte M; Keith PK; Bernstein JA; Lawo JP; Shetty H; Pollen M; Wieman L; Craig TJ;
    Allergy; 2024 Oct; ():. PubMed ID: 39370961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
    Hioki C; Oda Y; Moriwaki S; Fukunaga A
    J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
    Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
    Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.